Sökning: WFRF:(Leja Justyna 1982 )
> Hellman Per >
Preclinical Evaluat...
Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer
-
- Yu, Di, 1985- (författare)
- Uppsala universitet,Klinisk immunologi
-
- Leja, Justyna, 1982- (författare)
- Uppsala universitet,Klinisk immunologi
-
- Loskog, Angelica S., 1973- (författare)
- Uppsala universitet,Klinisk immunologi
-
visa fler...
-
- Hellman, Per (författare)
- Uppsala universitet,Endokrinkirurgi
-
- Giandomenico, Valeria (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Öberg, Kjell, 1946- (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Essand, Magnus (författare)
- Uppsala universitet,Klinisk immunologi
-
visa färre...
-
(creator_code:org_t)
- 2016-07-21
- 2017
- Engelska.
-
Ingår i: Neuroendocrinology. - : S. Karger. - 0028-3835 .- 1423-0194. ; 105:1, s. 54-66
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Cancer immunotherapy is becoming a cornerstone in the clinical care of cancer patients due to the breakthrough trials with immune checkpoint blockade antibodies and chimeric antigen receptor T cells. The next breakthrough in cancer immunotherapy is likely to be oncolytic viruses engineered to selectively kill tumor cells and deceive the immune system to believe that the tumor is a foreign entity that needs to be eradicated. We have developed AdVince, an oncolytic adenovirus for treatment of liver metastases from neuroendocrine tumor (NET). AdVince includes the gene promoter from human chromogranin A for selective replication in neuroendocrine cells, miR122 target sequences for reduced liver toxicity, and a cell-penetrating peptide in the capsid for increased infectivity of tumor cells and optimized spread within tumors. This paper describes the preclinical evaluation of AdVince on freshly isolated human gastrointestinal NET cells resected from liver metastases and freshly isolated human hepatocytes as well as in fresh human blood. AdVince selectively replicates in and kills NET cells. Approximately, 73-fold higher concentration of AdVince is needed to induce similar level of cytotoxicity in NET cells as in hepatocytes. AdVince did not activate complement or induce considerable amount of proinflammatory cytokines or chemokines in human blood. The data presented herein indicate that AdVince can be safely evaluated in a phase I/IIa clinical trial for patients with liver-dominant NET.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Neuroendocrine cancer; Oncolytic adenovirus; AdVince; Liver metastases; Immunotherapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Yu, Di, 1985-
-
Leja, Justyna, 1 ...
-
Loskog, Angelica ...
-
Hellman, Per
-
Giandomenico, Va ...
-
Öberg, Kjell, 19 ...
-
visa fler...
-
Essand, Magnus
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Neuroendocrinolo ...
- Av lärosätet
-
Uppsala universitet